Leukemia Recurrence: What to Ask

This page is for people whose leukemia has come back or did not respond to treatment, and for their families. It covers what the words mean, what to ask, what to bring, and when to get help fast.

Leukemia is four broad diseases, and relapse means something different in each. What follows draws on NCI's summary for acute myeloid leukemia, with a separate section for acute promyelocytic leukemia, a subtype of AML.

You may have acute lymphoblastic leukemia, chronic lymphocytic leukemia, or chronic myelogenous leukemia (CML). If so, the terms and salvage options on this page do not apply to you. Salvage options are treatments given after the first treatment fails. Take CML as an example. NCI defines relapsed CML as any sign of growth after a stable remission. That includes the BCR::ABL1 change showing up again on a FISH test after it had gone. NCI says a PCR test that still finds BCR::ABL1 during a long remission does not count as relapse on its own. For it, NCI names more tyrosine kinase inhibitors, such as ponatinib and asciminib. That is not a salvage chemotherapy conversation at all. Ask your team for the summary that matches your subtype.

The questions about preparation, documents and warning symptoms lower down do carry across.

NCI's clinical summary opens this section with a line most pages soften. No standard treatment regimen exists for refractory or recurrent acute myeloid leukemia.

That is not a gap in the writing. There is no single accepted best answer. It also explains why clinical trials sit high on the list here, not at the bottom.

Two words get mixed up and are worth splitting. Refractory means the leukemia never went into remission. Relapsed means it came back after one.

Ask how long your first remission lasted, in months, and how that affects your options now. Our page on relapsed or refractory leukemia sets out the figures behind that.

It helps to know what counts as the leukemia getting worse. The definition is based on numbers, not on impressions.

NCI's summary defines progressive disease by evidence of a rise in blasts, which are immature, abnormal blood cells. That means any of these:

• More than a 50% increase in marrow blasts
• More than a 50% increase in blasts in the blood without differentiation syndrome (a reaction to some leukemia drugs)
• New disease outside the marrow

So if the word progression is used, it is fair to ask which of those three applies.

NCI groups the options into three families: intensive salvage chemotherapy, reduced-intensity or targeted therapy, and a stem cell transplant using donor cells. Ask first which family is being proposed. That answer makes most of the talk clearer.

The drug plans, how well they work, FLT3, CD19, and CD22 testing, and questions to ask before a transplant are all on our page about relapsed or refractory leukemia. This page stays with the weeks around the news itself.

One thing to raise at this visit: ask whether the leukemia was tested again at relapse, not only at diagnosis. The genetic profile can change, and a targeted option can appear that was not there the first time. Liver blood tests are watched on some of those drugs, so ask what would pause treatment and who calls you.

APL is a separate subtype. NCI covers it in its own section. So a page about AML relapse can mislead here.

Recurrent APL is treated with arsenic trioxide, with or without chemotherapy. Stem cell transplant is also used. That is a different playbook from the salvage regimens above.

Newly diagnosed APL differs too. It uses all-trans retinoic acid and arsenic trioxide. Risk turns on the white blood cell count. Low to intermediate risk means a count of 10 x 10^9/L or less. NCI notes that lasting disease or relapse is rare in APL. Early deaths come from bleeding, differentiation syndrome, or infection, not resistant leukemia.

Three documents carry the weight:

• The original diagnostic report, with cytogenetics (chromosome) and molecular results
• The record of first-line treatment and how long remission lasted
• The current marrow report

Ask for the proposed regimen by name. Then ask for its complete remission rate in the population closest to this one. No standard regimen exists here. That comparison is the most useful thing to carry out of the appointment. Our page on AML risk groups explains how the genetics were sorted at diagnosis.

• Call 911 or go to an emergency department if bleeding will not stop, or you cough up or vomit blood. Leukemia can lower platelets, which help stop bleeding. NCI says APL can cause severe bleeding and blood clots. Do not drive yourself.
• Call 911 or go to an emergency department if you have a sudden severe headache, new confusion, weakness on one side, or trouble speaking. These can be signs of bleeding into the brain or of a clot. Do not drive yourself.
• Call your leukemia team at once, day or night, if you have a temperature of 100.4°F (38°C) or higher, or chills. CDC says fever during chemotherapy is a medical emergency: an infection can be life threatening, and you should be seen quickly. If you cannot get hold of the team quickly, go to an emergency department and tell them you have relapsed leukemia. See CDC's page on fever during chemotherapy.
• Call your care team right away, at any hour, if you notice new bruises, nosebleeds, bleeding gums, blood in urine or stool, or a rash of tiny red or purple spots. With platelets crowded out, these can be the first signs of more serious bleeding.
• Call your care team right away if you are getting steadily more tired, breathless on light activity, or paler than usual. NCI lists tiredness and paleness among the signs of AML. For chest pain or trouble breathing, call 911.

• National Cancer Institute, Acute Myeloid Leukemia Treatment (PDQ) - Health Professional Version, accessed August 6, 2026
• National Cancer Institute, Chronic Myelogenous Leukemia Treatment (PDQ) - Health Professional Version, accessed August 6, 2026
• National Cancer Institute, Acute Myeloid Leukemia Treatment (PDQ) - Patient Version, accessed August 11, 2026
• National Cancer Institute, Infection and Neutropenia During Cancer Treatment, accessed August 11, 2026